Prospects for the development of long-acting formulations of human somatropin.
AffiliationDepartment of Endocrinology, Christie Hospital, Manchester, UK.
MetadataShow full item record
AbstractIn healthy humans, growth hormone (GH) is secreted in distinct pulses with an underlying nyctohemeral pattern. Current forms of somatropin replacement are unable to closely mimic such a release pattern, but are still able to exert the beneficial action of GH. A limited number of short-term studies in rodents and humans suggest that longitudinal growth may be superior when somatropin is given with a pulsatile mode of administration, whereas hepatic insulin-like growth factor-I generation and beneficial changes in body composition appear to be equal or even enhanced with continuous somatropin administration.Recent developments in drug delivery technology have allowed the use of slow-release preparations of somatropin in humans. The most successful technology so far has been the encapsulation of somatropin molecules in poly(D,L-lactic-co-glycolic acid) biodegradable microspheres. Pharmacokinetic and pharmacodynamic data have been published on two such preparations; Nutropin Depot((R)) and hGH-Biosphere((R)). The latter has a superior release profile, but outcomes data from multicenter trials in both children and adults have been presented for the former: catch-up growth was observed in children, although to a lesser degree than historic comparative data obtained with the use of daily somatropin injections and the effects on metabolic derangements in GH-deficient patients appeared similar to those observed with daily injections. Improved sustained-release somatropin preparations will need further study of their long-term efficacy, but, if successful, will be highly attractive in terms of patient compliance and convenience.
CitationProspects for the development of long-acting formulations of human somatropin. 2006, 5 (3):139-45 Treat Endocrinol
JournalTreatments in Endocrinology
- A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile.
- Authors: Jostel A, Mukherjee A, Alenfall J, Smethurst L, Shalet SM
- Issue date: 2005 May
- Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
- Authors: Kemp SF, Fielder PJ, Attie KM, Blethen SL, Reiter EO, Ford KM, Marian M, Dao LN, Lee HJ, Saenger P
- Issue date: 2004 Jul
- A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.
- Authors: Silverman BL, Blethen SL, Reiter EO, Attie KM, Neuwirth RB, Ford KM
- Issue date: 2002 May
- Novel long-acting GH preparations.
- Authors: Doknic M, Stojanovic M, Popovic V
- Issue date: 2014 Dec
- The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.
- Authors: Cook DM, Biller BM, Vance ML, Hoffman AR, Phillips LS, Ford KM, Benziger DP, Illeperuma A, Blethen SL, Attie KM, Dao LN, Reimann JD, Fielder PJ
- Issue date: 2002 Oct